Press Releases ›

6-Jan-2009
FDA approves once-yearly Reclast® for osteoporosis in men

12-Dec-2008
First Phase III results for FTY720, a novel oral therapy for MS, show superior efficacy compared to interferon beta-1a

13-Nov-2008
US FDA approves 30-minute onset of action for Focalin® XR, bringing potential benefits to ADHD patients during early morning period

11-Nov-2008
Tekturna®, first approved direct renin inhibitor, effectively lowers high blood pressure in elderly patients

11-Nov-2008
Study shows potential benefits of Xolair® in treating children suffering from moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.